Orders of magazines and newspapers ship free anywhere in U.S.

Biotech's Next Revolution | Barron's, Sept. 2, 2019

Biotech's Next Revolution | Barron's, Sept. 2, 2019

Regular price $13.00 Sale

Barron's print edition as published Sept. 2, 2019.

On the Cover: Biotech's Next Revolution ... If It Works

Messenger RNA seeks to make the body its own drug factory. Can the upstarts pull it off? By Josh Nathan-Kazis

And: Fall Forecasts for Stocks and Bonds

Also in this issue:

  • The opioid ruling against Johnson & Johnson, while not legal precedent, could prompt other drugmakers to settle claims. By Josh Nathan-Kazis
  • Two Hedge Titans’ Reinsurers to Buy -- Daniel Loeb’s Third Point Re and David Einhorn’s Greenlight Capital both look cheap. By Andrew Bary
  • Insights That Stock Screens Can’t Match -- The MFAM Global Opportunities fund. By Lewis Braham
  • Don’t Make These 401(k) Mistakes When You Switch Jobs. By Sarah Max
  • Growth Companies in the Cannabis Field -- Rob Fagan of GMP Securities. By Bill Alpert 

    VOL. XCIX No. 35

    Pages: 72